These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 11772420)

  • 1. A general assessment of the safety of HMG CoA reductase inhibitors (statins).
    Black DM
    Curr Atheroscler Rep; 2002 Jan; 4(1):34-41. PubMed ID: 11772420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rhabdomyolysis and statin therapy: relevance to the elderly.
    Sica DA; Gehr TW
    Am J Geriatr Cardiol; 2002; 11(1):48-55. PubMed ID: 11773716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current perspectives on statins.
    Maron DJ; Fazio S; Linton MF
    Circulation; 2000 Jan; 101(2):207-13. PubMed ID: 10637210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust.
    Davidson MH
    Drugs; 2001; 61(2):197-206. PubMed ID: 11270938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
    Jamal SM; Eisenberg MJ; Christopoulos S
    Am Heart J; 2004 Jun; 147(6):956-65. PubMed ID: 15199341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Policosanol safely down-regulates HMG-CoA reductase - potential as a component of the Esselstyn regimen.
    McCarty MF
    Med Hypotheses; 2002 Sep; 59(3):268-79. PubMed ID: 12208152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Brief Drug Class Review: Considerations for Statin Use, Toxicity, and Drug Interactions.
    Wooten JM
    South Med J; 2018 Jan; 111(1):39-44. PubMed ID: 29298368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of childhood hypercholesterolemia with HMG-CoA reductase inhibitors.
    Duplaga BA
    Ann Pharmacother; 1999 Nov; 33(11):1224-7. PubMed ID: 10573325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of therapeutic interchangeability of HMG-CoA reductase inhibitors.
    Chong PH
    Ann Pharmacother; 2002 Dec; 36(12):1907-17. PubMed ID: 12452755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).
    Oliveira EF; Santos-Martins D; Ribeiro AM; Brás NF; Cerqueira NS; Sousa SF; Ramos MJ; Fernandes PA
    Expert Opin Ther Pat; 2016 Nov; 26(11):1257-1272. PubMed ID: 27537201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
    Williams D; Feely J
    Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [HMG-CoA reductase inhibitors in prevention of cardiovascular diseases: new mechanisms, aspects and trials].
    Wojakowski W; Gmiński J
    Przegl Lek; 2000; 57(5):291-5. PubMed ID: 11057120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HMG CoA reductase inhibitors.
    Feussner G
    Curr Opin Lipidol; 1994 Feb; 5(1):59-68. PubMed ID: 15559032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins).
    Igel M; Sudhop T; von Bergmann K
    Eur J Clin Pharmacol; 2001 Aug; 57(5):357-64. PubMed ID: 11599653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
    Evans M; Rees A
    Drug Saf; 2002; 25(9):649-63. PubMed ID: 12137559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Adverse effects of statins].
    Andréjak M; Gras V; Massy ZA; Caron J
    Therapie; 2003; 58(1):77-83. PubMed ID: 12822204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.